trending Market Intelligence /marketintelligence/en/news-insights/trending/djfrlmhqkkpf7i8c9d2gkw2 content esgSubNav
In This List

Arcus Biosciences prices $120M IPO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Arcus Biosciences prices $120M IPO

Arcus Biosciences Inc. priced its IPO of 8 million common shares at $15 apiece.

The Hayward, Calif.-based company expects total gross proceeds of about $120 million. The company also granted underwriters an option to buy an additional 1.2 million common shares.

In a separate filing, Arcus Biosciences registered an additional 1,035,000 shares, also priced $15 apiece. The shares will bring the offering size up to 9.2 million shares, and raise additional gross proceeds of about $15.5 million.

The company's shares are expected to begin trading on the NYSE under the symbol RCUS on March 15.

The offering is expected to close March 19.

Citigroup, Goldman Sachs & Co. LLC and Leerink Partners are acting as joint book-running managers for the offering.

Arcus Biosciences is a clinical-stage biopharmaceutical company, which engages in developing and commercializing cancer immunotherapies in the U.S.